Furthermore, the number of cleaved caspase-3-positive tumor cells increased significantly in the combination treatment group, indicating that inhibition of USP14 together with anti-PD-1 was a highly effective therapeutic strategy for CRC (Supplementary Fig. 6e). The gene discussed is USP14; the disease is colorectal carcinoma.